Mazdutide for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Mazdutide, a once-weekly injectable prescription medication modeled on a natural gut hormone, is approved in China for weight management and type 2 diabetes. Evidence is strong for substantial weight loss that grows with dose, and for lower blood sugar and blood fats; effects on heart attacks, strokes, deaths or aging are untested. Digestive side effects are common, and nearly all data come from its two developers. (Full Review)

Protocol

Approved maintenance doses
4 mg or 6 mg once weekly
For weight management; 9 mg studied in GLORY-2, 10 mg and 16 mg investigational
Titration
Dose steps every 4 weeks
Lilly's US trial: 1.5 mg, then 3 mg and 6 mg, adding 2–4 mg per step to target; GLORY-2 used 3 mg steps
Single or split dose
One subcutaneous injection weekly
Same weekday, any time of day, with or without food; split dosing not studied
Time to effect
Body weight
Within weeks
4.8–6.4% by week 12; no plateau by 48 weeks
Glycemic control
By 24 weeks
HbA1c falls
Liver fat
By 32 weeks
Reductions evident

Benefits

Contraindications
  • Personal or family history of medullary thyroid carcinoma, or MEN2
  • Pregnancy, breastfeeding, or conception planned within 2 months
  • Under 18 years
  • BMI below 24 kg/m², or 24–27.9 kg/m² without a weight-related condition
  • History of pancreatitis
  • Type 1 diabetes
  • Severe gastroparesis
  • Prior serious hypersensitivity to mazdutide or its inactive ingredients
Key Interactions
Theoretical (inferred from mechanism)
  • Metformin
  • Insulin and sulfonylureas (glimepiride, gliclazide)
  • Other GLP-1-based drugs (semaglutide, tirzepatide)
  • Narrow-margin oral drugs (warfarin, levothyroxine)
  • Oral contraceptives (ethinyl estradiol with levonorgestrel)
  • Blood pressure drugs and diuretics (amlodipine, furosemide)
  • NSAIDs (ibuprofen, naproxen), over the counter
  • Gut-slowing drugs (oxycodone, oxybutynin)
  • Glucose-lowering supplements (berberine, chromium picolinate)
  • Blood-pressure-lowering supplements (beetroot nitrate, aged garlic extract)
  • Bulk fiber supplements (psyllium, glucomannan)
  • Alcohol
  • Prolonged fasting or very-low-calorie diets
  • Sedation and general anesthesia

Risk & Side Effects

  • High: Gastrointestinal Adverse Events; Heart Rate Increase
  • Medium: Fatigue; Gallbladder Disease; Dehydration and Acute Kidney Injury; Cardiac Rhythm Findings
  • Low: Hypoglycemia; Lean Mass Loss; Pancreatitis; Retained Stomach Contents During Procedures; Diabetic Retinopathy Complications; Hypersensitivity Reactions
  • Speculative: Medullary Thyroid Carcinoma; HDL Cholesterol Decrease

Monitoring

Marker Target Why
Body weight and waist circumference No established target; track percentage change from own baseline Primary effect
HbA1c Below 7.0% in type 2 diabetes Expected to change; low values with insulin or sulfonylureas flag hypoglycemia risk
Fasting glucose 70–99 mg/dL Hypoglycemia safety check; expected to change
Lipid panel (LDL, HDL, triglycerides) No established target; track change from own baseline LDL and triglycerides fall; HDL may fall
ALT and AST 7–55 U/L for ALT, 8–48 U/L for AST Expected to fall with liver fat; a rise is a safety check
Liver fat (MRI-PDFF) Below 5% Expected to change
Serum uric acid 3.5–7.2 mg/dL Expected to change
Lipase and amylase Lipase 13–60 U/L, amylase 40–140 U/L Pancreatitis safety check
Creatinine and eGFR Creatinine 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women); eGFR: track change from own baseline Kidney injury safety check
Resting heart rate 60–100 beats/min Heart-rate rise safety check
Lean and fat mass (DXA) No established target; track lean mass change from own baseline Fat and lean mass fall

Cadence: Baseline assessment before starting (retinal examination added in diabetes); weight and resting heart rate weekly during titration; symptoms and glucose (if diabetic) at each dose step; labs at 12 weeks, then every 3–6 months; liver fat imaging and DXA at 6–12 months, then yearly

Qualitative Assessment

  • Appetite control and reduced food preoccupation
  • Digestive tolerance (nausea, bowel habits)
  • Energy levels and exercise capacity
  • Strength on standard lifts as a muscle proxy